RxDoctor Payments DataLook up a doctor →

Jennifer Lynch, MD

Neurology · Springfield, MONPI 1700829165

Payments from drug & device makers

$88,383in general payments, 2019–2025

Across 754 payments — averaging $117.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$55K
  • AbbVie$19K
  • Jazz Pharmaceuticals Inc.$1K
  • Livanova USA, Inc.$969
  • Inspire Medical Systems, Inc.$895
  • Harmony Biosciences LLC$745
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$15,89448%
  • Travel & lodging$1,4024%
  • Food & beverage$15,78547%
  • Education$2781%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)33$54,708
AbbVie(2 entities)159$19,379
Jazz Pharmaceuticals Inc.44$1,416
Livanova USA, Inc.10$969
Inspire Medical Systems, Inc.7$895
Harmony Biosciences LLC21$745
Sanofi33$725
EMD Serono, Inc.33$586
Supernus Pharmaceuticals, Inc.35$533
UCB, Inc.28$486
Argenx US, Inc.23$479
Eisai Inc.21$461
W. L. Gore & Associates, Inc.2$450
Lilly USA, LLC16$378
Amgen(2 entities)13$377
Pfizer26$377
Lundbeck LLC14$353
Biogen17$345
Axsome Therapeutics, Inc.6$307
ANI Pharmaceuticals, Inc.14$285
Biohaven Pharmaceuticals, Inc.21$274
Biohaven Pharmaceutical Holding Company Ltd.15$259
Novartis12$252
Portola Pharmaceuticals, LLC5$240
Acadia Pharmaceuticals Inc14$228
SK Life Science, Inc.5$199
AstraZeneca9$194
Genentech USA, Inc.6$189
Kyowa Kirin, Inc.11$180
Neurocrine Biosciences, Inc.8$166
Amneal Pharmaceuticals LLC9$161
Catalyst Pharmaceuticals, Inc.2$140
Avadel CNS Pharmaceuticals, LLC1$125
Bristol Myers Squibb7$122
Teva Pharmaceuticals USA, Inc.7$116
MDD US Operations, LLC6$103
Greenwich Biosciences, Inc.1$98
Acorda Therapeutics, Inc4$77
Johnson & Johnson5$77
Tanabe Pharma America, Inc.5$76
Grifols USA, LLC4$70
Sunovion Pharmaceuticals Inc.4$67
Xeris Pharmaceuticals, Inc.3$64
Banner Life Sciences, LLC4$60
CSL Behring3$57
Avion Pharmaceuticals3$55
Piramal Critical Care1$53
Otsuka America Pharmaceutical, Inc.3$52
Mallinckrodt Hospital Products Inc.3$49
Neurelis, Inc.2$49
Amylyx Pharmaceuticals, Inc.2$44
Adamas Pharmaceuticals, Inc.2$40
Alnylam Pharmaceuticals Inc.2$36
Abbott2$35
Ipsen Biopharmaceuticals, Inc2$29
Merz Pharmaceuticals, LLC1$24
Impel Pharmaceuticals Inc.1$17
Bausch Health US, LLC1$16
Aprecia Pharmaceuticals, LLC1$15
Amicus Therapeutics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$88,383 in reported general payments places this provider in the 85th percentile of 381 neurology providers in Missouri.

See all neurology providers in Missouri

Medicare billing

Part B allowed, 2024
$56,201
Medicare patients
393
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate28$410,738
RebifInterferon Beta-1a/Albumin13$158,316
BriviactBrivaracetam81$123,080
Kesimpta PenOfatumumab12$102,794
Vigabatrin13$85,973
Nurtec OdtRimegepant Sulfate71$79,718
NuplazidPimavanserin Tartrate18$76,331
Emgality PenGalcanezumab-Gnlm45$60,220
EpidiolexCannabidiol (Cbd)13$57,724
XcopriCenobamate43$56,791
QuliptaAtogepant36$47,752
UbrelvyUbrogepant37$40,509
Aimovig AutoinjectorErenumab-Aooe54$40,050
NayzilamMidazolam14$15,142
Rasagiline Mesylate59$14,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$586$158,31613 claims
UCB, Inc.Briviact, Nayzilam$486$138,22295 claims
AbbVieQulipta, Ubrelvy$19,379$88,26173 claims
PfizerNurtec Odt$377$79,71871 claims
Acadia Pharmaceuticals IncNuplazid$228$76,33118 claims
SK Life Science, Inc.Xcopri$199$56,79143 claims
Axsome Therapeutics, Inc.Sunosi$307$14,53611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 381 neurology providers in Missouri.

Other neurology in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →